Wells Fargo
TARA icon

Wells Fargo’s Protara Therapeutics TARA Stock Holding History

Wells Fargo’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$209K Buy
54,596
+23,899
+78% +$114K ﹤0.01% 5180
2026
Q1 		$160K Sell
30,697
-9,105
-23% -$53.9K ﹤0.01% 4831
2025
Q4 		$212K Buy
39,802
+15,037
+61% +$83.6K ﹤0.01% 5034
2025
Q3 		$108K Buy
24,765
+4,038
+19% +$13.1K ﹤0.01% 5281
2025
Q2 		$62.8K Buy
+20,727
New +$71.5K ﹤0.01% 5428
2024
Q3 		– Sell
-500
Closed -$1.04K – 7076
2024
Q2 		$1.04K Sell
500
-70
-12% -$205 ﹤0.01% 6087
2024
Q1 		$2.29K Buy
570
+1
+0.2% +$3 ﹤0.01% 6008
2023
Q4 		$1.07K Buy
569
+4
+0.7% +$6 ﹤0.01% 6207
2023
Q3 		$944 Buy
565
+2
+0.4% +$5 ﹤0.01% 6217
2023
Q2 		$1.35K Buy
563
+3
+0.5% +$9 ﹤0.01% 6268
2023
Q1 		$1.75K Buy
560
+1
+0.2% +$3 ﹤0.01% 6253
2022
Q4 		$1.5K Buy
559
+1
+0.2% +$3 ﹤0.01% 6079
2022
Q3 		$1K Sell
558
-8
-1% -$27 ﹤0.01% 6469
2022
Q2 		$1K Buy
566
+6
+1% +$22 ﹤0.01% 6608
2022
Q1 		$3K Hold
560
– – ﹤0.01% 6601
2021
Q4 		$3K Hold
560
– – ﹤0.01% 6825
2021
Q3 		$3K Buy
560
+1
+0.2% +$8 ﹤0.01% 6506
2021
Q2 		$6K Sell
559
-67,733
-99% -$767K ﹤0.01% 6298
2021
Q1 		$1.07M Buy
68,292
+55,182
+421% +$1.02M ﹤0.01% 4194
2020
Q4 		$317K Sell
13,110
-3,453
-21% -$74.4K ﹤0.01% 4844
2020
Q3 		$279K Buy
16,563
+7,800
+89% +$181K ﹤0.01% 4766
2020
Q2 		$257K Buy
8,763
+8,657
+8,167% +$268K ﹤0.01% 4764
2020
Q1 		$2K Buy
+106
New +$3.09K ﹤0.01% 6011
2016
Q2 		– Sell
-31
Closed -$10K – 6315
2016
Q1 		$10K Buy
31
+12
+63% +$3.87K ﹤0.01% 5694
2015
Q4 		$12K Buy
19
+18
+1,800% +$10.6K ﹤0.01% 5702
2015
Q3 		$1K Sell
1
-9
-90% -$5.57K ﹤0.01% 6080
2015
Q2 		$7K Buy
+10
New +$6.19K ﹤0.01% 5920

Other funds holding TARA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

Wells Fargo's TARA Position: Q2 2026 in Review

Wells Fargo increased its Protara Therapeutics (TARA) stake by 78% in Q2 2026, buying an estimated $114K and bringing the position to 54,596 shares worth $209K. The position accounts for ﹤0.01% of the portfolio, ranked #5180.

Wells Fargo first reported a position in TARA in Q2 2015 and has held it in 27 quarters since. The position peaked at $1.07M in Q1 2021. 120 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

  • Wells Fargo held 54,596 shares of Protara Therapeutics worth $209K as of Q2 2026.
  • Wells Fargo bought 23,899 Protara Therapeutics shares in Q2 2026, an estimated $114K.
  • Protara Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #5180 holding.
  • Wells Fargo first reported a position in Protara Therapeutics in Q2 2015 and has held it in 27 quarters since.
  • Wells Fargo's Protara Therapeutics position peaked at $1.07M in Q1 2021.
  • 120 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.